Hung Shih-Chang, Hung Shih-Rong, Lin Cheng-Li, Lai Shih-Wei, Hung Hung-Chang
Department of Emergency Medicine, Nantou Hospital, Nantou, Taiwan.
Department of Pharmacy, Erlin Christian Hospital, Changhua, Taiwan.
Am J Gastroenterol. 2015 Oct;110(10):1490-6. doi: 10.1038/ajg.2015.259. Epub 2015 Sep 1.
This study evaluated whether there is an association between the use of celecoxib and acute pancreatitis in Taiwan.
We conducted a case-control study using the database of the Taiwan National Health Insurance Program. The participants comprised 5,095 subjects, aged 20-84 years, with a first admission episode of acute pancreatitis from 2000 to 2011 as the cases and 20,380 randomly selected sex-matched and age-matched subjects without acute pancreatitis as the controls. The absence of celecoxib prescription was defined as "never used." Current use of celecoxib was defined as subjects who had received at least one prescription for celecoxib within 3 days before diagnosis with acute pancreatitis. A multivariate unconditional logistic regression model was used to calculate the odds ratio (OR) and 95% confidence interval (CI) for acute pancreatitis associated with the use of celecoxib.
Compared with subjects who never used celecoxib, the adjusted OR of acute pancreatitis was 5.62 in subjects with current use of celecoxib (95% CI=3.33-9.46).
The current use of celecoxib is associated with an increased risk of acute pancreatitis.
本研究评估在台湾地区塞来昔布的使用与急性胰腺炎之间是否存在关联。
我们利用台湾全民健康保险计划数据库进行了一项病例对照研究。参与者包括5095名年龄在20至84岁之间的受试者，他们在2000年至2011年期间首次因急性胰腺炎入院作为病例组，以及20380名随机选取的、性别和年龄匹配的无急性胰腺炎的受试者作为对照组。未开具塞来昔布处方被定义为“从未使用过”。当前使用塞来昔布被定义为在诊断为急性胰腺炎前3天内至少接受过一次塞来昔布处方的受试者。采用多变量无条件逻辑回归模型计算与使用塞来昔布相关的急性胰腺炎的比值比（OR）和95%置信区间（CI）。
与从未使用过塞来昔布的受试者相比，当前使用塞来昔布的受试者急性胰腺炎的校正OR为5.62（95%CI = 3.33 - 9.46）。
当前使用塞来昔布与急性胰腺炎风险增加相关。
